Associate
Yieyie has handled various aspects of trial preparation, including fact and expert discovery, depositions of key witnesses and experts, and motion practice, along with other pre-litigation due diligence and position analysis. She also has worked on multiple IPR cases on behalf of petitioners or patent owners and has been involved in all aspects of those cases, including developing key arguments, preparing and sitting in expert depositions, drafting expert declarations and key papers, and preparing for oral arguments. In addition, Yieyie has conducted a variety of due diligence analysis in the biotechnological field for licensing, acquisition, freedom-to-operate, and startup fundraising.
Yieyie's scientific background is in molecular and cancer biology. Her graduate research focused on identifying novel genes involved in axon guidance during the development of the nervous system, and her new findings were published in peer-reviewed scientific journals. During her post-doctoral research period at the Dana-Farber Cancer Institute, she studied epigenetic chromatin-remodeling complexes and identified tumor suppressor candidates that interact with oncogenes during cellular transformation and tumorigenesis.
While in law school, Yieyie also paid close attention to the development of Chinese intellectual property law. Her articles on Chinese patent law have been published by peer-reviewed law journals.
Grünenthal GmbH et al. v. Actavis Elizabeth LLC et al.
Member of team that represented Grünenthal GmbH in multiple Hatch-Waxman suits involving analgesic drugs Nucynta® and Nucynta® ER; the district court enjoined the defendants from marketing generic versions until patent expiry.
2:13-cv-04507, -06929, -07803; 2:14-cv-03941, -04617; 2:15-cv-06797, D.N.J., Judges Cecchi, Falk
Eli Lilly and Company v. Actavis Labs. UT Inc.
Member of team representing Eli Lilly in Hatch-Waxman action against several defendants relating to Cialis®.
1:16-cv-01119, E.D. Va., Judges Nachmanoff, Trenga
Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Member of team representing Eli Lilly in an appeal from a Patent Trial and Appeal Board (PTAB) decision in an IPR case.
IPR2014-00693, -00752, PTAB, Judges Green, Prats, Snedden
16-1547, Fed. Cir., Judges Bryson, Moore, Newman
AstraZeneca LP v. SigmaPharm Laboratories
Member of team representing AstraZeneca in Hatch-Waxman litigations against several defendants involving the blood-thinning drug Brilinta®.
1:15-cv-01000, D. Del., Judge Andrews
Actelion Pharmaceuticals v. ICOS Corp.
Member of team representing ICOS in two IPRs defending their formulation patents.
IPR2015-00561, -00562, PTAB, Judges Mitchell, Snedden, Yang
Eli Lilly and Company v. Teva Pharmaceuticals International
Member of team representing Eli Lilly in multiple IPRs involving antibody patents.
IPR2018-01422; -01423; -01424; -01425; -01426; -01427; -01710, -01711, -01712, PTAB
Prosecution First Blog
Then You Didn’t See Them; Now You Do: Co-Inventors Added Then You Didn’t See Them; Now You Do: Co-Inventors Added
July 24, 2020
Federal Circuit IP Blog
“Wherein” Clauses May Be Limiting “Wherein” Clauses May Be Limiting
September 10, 2019
Federal Circuit IP Blog
Claim Amendment to Avoid Unrelated Prior Art Protein Is Unrelated to Codon-Randomized Versions of Protein-at-Issue and Do Not Trigger Prosecution History Estoppel Under the Tangential Exception Claim Amendment to Avoid Unrelated Prior Art Protein Is Unrelated to Codon-Randomized Versions of Protein-at-Issue and Do Not Trigger Prosecution History Estoppel Under the Tangential Exception
August 28, 2019
Federal Circuit IP Blog
The Federal Circuit Adopts a Liberal, Notice-Based Interpretation of the Relation Back Doctrine Under Rule 15(c) The Federal Circuit Adopts a Liberal, Notice-Based Interpretation of the Relation Back Doctrine Under Rule 15(c)
August 26, 2019
Federal Circuit IP Blog
The Tangential Exception to Prosecution History Estoppel Should Not Be Viewed Rigidly The Tangential Exception to Prosecution History Estoppel Should Not Be Viewed Rigidly
August 23, 2019
Panel Discussion
Intellectual Property Strategies for Startups: Grow and Exit Intellectual Property Strategies for Startups: Grow and Exit
April 27, 2019
Burlingame
Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.